Ignite Creation Date:
2024-05-05 @ 5:36 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00490451
Status:
COMPLETED
Last Update Posted:
2019-09-18
First Post:
2007-06-20
Brief Title:
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma
Status:
COMPLETED
Status Verified Date:
2019-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of the study is to estimate the time from the first dose of LY573636-sodium hereafter referred to as LY573636 to the date your physician determines that your disease has progressed or worsened
Detailed Description:
Patients will receive a 2-hour intravenous infusion of study drug LY573636 once every 21 days or 28 days depending on their target dose Radiological imaging scans will be performed before the first dose of study drug and then after every other treatment Patients will be assessed for clinical progression at every visit and for response approximately every 42 days or 56 days every other cycle
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H8K-MC-JZAD | OTHER | Eli Lilly and Company | None |